IRADIMED Inkomsten in het verleden
Verleden criteriumcontroles 5/6
IRADIMED heeft de winst zien groeien met een gemiddeld jaarlijks percentage van 25.4%, terwijl de Medical Equipment-industrie de winst zag groeien met 15.3% per jaar. De inkomsten zijn gegroeid met een gemiddeld jaarlijks percentage van 17.4%. Het rendement op eigen vermogen van IRADIMED is 24%, en het heeft een nettomarge van 27.4%.
Belangrijke informatie
25.38%
Groei van de winst
24.88%
Groei van de winst per aandeel
| Medical Equipment Groei van de industrie | 8.90% |
| Inkomstengroei | 17.40% |
| Rendement op eigen vermogen | 23.97% |
| Nettomarge | 27.36% |
| Laatste winstupdate | 31 Mar 2026 |
Recente prestatie-updates uit het verleden
Recent updates
Narratiefupdate • Jun 04
IRMD: 2026 Guidance And Bullish Coverage Will Support Further Re Rating
Analysts have nudged their price target on IRADIMED slightly lower, from about $118.67 to $118.00. They are refining assumptions around discount rates, revenue growth, margins and future P/E expectations following recent bullish Street coverage.Narratiefupdate • Apr 30
IRMD: 2026 Dividend And Guidance Will Anchor Bullish Re Rating
Analysts nudged their price targets for IRADIMED higher, with recent Street research citing supportive views on the business. These views help explain the updated fair value of $118.67 along with a slightly adjusted discount rate and forward P/E assumptions.Narratiefupdate • Apr 12
IRMD: 2026 Dividend And Guidance Will Support Bullish Re-Rating
Analysts have trimmed their fair value estimate for IRADIMED from about $120 to roughly $118.67, citing revised assumptions for revenue growth, profit margins and future P/E. At the same time, recent Street research, including fresh bullish initiations and higher price targets, continues to support a constructive view on the stock.Narratiefupdate • Mar 26
IRMD: 2026 Guidance And Dividend Will Support Higher Price Re-Rating
Analysts have lifted their price target on IRADIMED by a double digit dollar amount, citing updated valuation work that reflects refined assumptions, including a fair value of $120, a discount rate of 7.69%, revenue growth of 9.70%, a profit margin of 27.77% and a future P/E of 58.53. Analyst Commentary Recent research points to a tighter alignment between IRADIMED's valuation work and updated assumptions on growth, profitability and the P/E investors may be willing to pay.Narratiefupdate • Mar 11
IRMD: 2026 Guidance And Dividend Will Support Higher P/E Repricing
Narrative Update on IRADIMED The analyst price target on IRADIMED has been raised by $20 to $120. Analysts cite updated valuation work that incorporates a slightly higher discount rate and future P/E assumption, along with recent Street research that supports the new level.Narratiefupdate • Feb 25
IRMD: 2026 Guidance And Dividends Will Support Higher Earnings Multiple
Analysts have lifted their fair value estimate for IRADIMED from $99 to $120, citing updated assumptions around slightly different revenue growth, profit margin expectations, discount rate, and a higher future P/E. These revisions align with recent Street price target increases reported by firms such as Lake Street and Roth Capital.Narratiefupdate • Feb 10
IRMD: Stable Outlook Will Rely On 2026 Guidance And Dividend Support
Analysts have kept their price target for IRADIMED effectively unchanged at $99.00. They cite only marginal tweaks to discount rate, revenue growth, profit margin, and future P/E assumptions rather than any shift in their core view on the company.Narratiefupdate • Jan 27
IRMD: Record Backlog And Raised Guidance Will Support Premium Yet Balanced Outlook
Narrative Update Analysts have nudged their price targets for IRADIMED higher into a US$98 to US$100 range, reflecting updated forward estimates, a record backlog, the recent beat and raise quarter, and expectations tied to the 3870 IV Pump launch. Analyst Commentary Analysts updating their models for IRADIMED are broadly constructive, with recent research focused on how the latest quarter and product pipeline translate into earnings power and valuation support.Narratiefupdate • Jan 12
IRMD: Raised Guidance And Backlog Support Premium While Risks Keep Outlook Balanced
Narrative Update Introduction Analysts have lifted their price expectations for IRADIMED to a range of about $98 to $100, citing higher forward estimates, a record backlog that supports near term visibility, and confidence around the 3870 IV Pump launch as key reasons for the updated targets. Analyst Commentary Recent Street research on IRADIMED reflects a clear tilt toward optimism, with price targets lifted into the high double digits following the latest quarterly update.Narratiefupdate • Dec 14
IRMD: Raised Guidance And Backlog Will Support Premium Amid Execution Risks
Analysts have nudged their average price target on IRADIMED higher, to a level just under $100 per share from the low $90s, citing stronger than expected Q3 results, raised full year guidance, and growing confidence that a robust backlog and upcoming product launches will support sustained growth. Analyst Commentary Bullish analysts highlight that the recent upside surprise on both revenue and earnings, along with raised full year guidance, reinforces a view that IRADIMED is executing ahead of prior expectations and can support a higher valuation multiple.Narratiefupdate • Nov 29
IRMD: Raised Guidance And Strong Backlog Will Maintain Premium Despite Execution Risks
IRADIMED’s analyst price target has been raised from $90 to a range approaching $100 per share. Analysts cite the company’s recent sales and earnings outperformance, increased full-year guidance, and strong prospects from product innovation and backlog growth.Narratiefupdate • Nov 15
IRMD: Raised Guidance And Record Backlog Are Set To Drive Continued Momentum
Analysts have raised their price target for IRADIMED significantly, from $82.50 to $99.00. They cited stronger-than-expected quarterly results, improved guidance, and a robust outlook driven by a growing backlog and product innovation.Narratiefupdate • Nov 01
IRMD: Index Addition and Strong Margins Will Support Measured Upside
Analysts have raised their price target for IRADIMED from $73.50 to $82.50. They cite modest improvements in projected profit margins and valuation multiples as key drivers behind the adjustment.Analyseartikel • Oct 09
Should You Be Adding IRADIMED (NASDAQ:IRMD) To Your Watchlist Today?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Analyseartikel • Aug 13
IRADIMED CORPORATION's (NASDAQ:IRMD) Shares Climb 27% But Its Business Is Yet to Catch Up
Despite an already strong run, IRADIMED CORPORATION ( NASDAQ:IRMD ) shares have been powering on, with a gain of 27% in...Analyseartikel • Aug 08
IRADIMED's (NASDAQ:IRMD) Profits May Not Reveal Underlying Issues
NasdaqGM:IRMD 1 Year Share Price vs Fair Value Explore IRADIMED's Fair Values from the Community and select yours The...Analyseartikel • Jun 01
Shareholders Would Enjoy A Repeat Of IRADIMED's (NASDAQ:IRMD) Recent Growth In Returns
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
Nieuw narratief • Sep 24
Innovative IV Pumps And Monitor Expansion Set To Spearhead Revenue Surge And Enhance Profit Margins
Introduction of the new 3870 IV pump and expansion in the Monitor business signal potential significant revenue growth and increases in product line revenue.Analyseartikel • Aug 08
IRADIMED's (NASDAQ:IRMD) Solid Profits Have Weak Fundamentals
Despite announcing strong earnings, IRADIMED CORPORATION's ( NASDAQ:IRMD ) stock was sluggish. Our analysis uncovered...Analyseartikel • Feb 23
If EPS Growth Is Important To You, IRadimed (NASDAQ:IRMD) Presents An Opportunity
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Analyseartikel • Feb 07
Getting In Cheap On IRadimed Corporation (NASDAQ:IRMD) Is Unlikely
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 16x, you may...Analyseartikel • Nov 06
Should You Investigate IRadimed Corporation (NASDAQ:IRMD) At US$45.06?
While IRadimed Corporation ( NASDAQ:IRMD ) might not be the most widely known stock at the moment, it led the NASDAQCM...Analyseartikel • Oct 13
Calculating The Intrinsic Value Of IRadimed Corporation (NASDAQ:IRMD)
Key Insights Using the 2 Stage Free Cash Flow to Equity, IRadimed fair value estimate is US$36.84 IRadimed's US$37.31...Analyseartikel • Feb 05
At US$41.26, Is It Time To Put IRadimed Corporation (NASDAQ:IRMD) On Your Watch List?
While IRadimed Corporation ( NASDAQ:IRMD ) might not be the most widely known stock at the moment, it led the NASDAQCM...Opbrengsten en kosten
Opbrengsten en kosten
Hoe IRADIMED geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 31 Mar 26 | 86 | 24 | 35 | 3 |
| 31 Dec 25 | 84 | 22 | 35 | 3 |
| 30 Sep 25 | 81 | 21 | 34 | 3 |
| 30 Jun 25 | 78 | 21 | 33 | 3 |
| 31 Mar 25 | 75 | 20 | 33 | 3 |
| 31 Dec 24 | 73 | 19 | 32 | 3 |
| 30 Sep 24 | 71 | 19 | 31 | 3 |
| 30 Jun 24 | 69 | 19 | 30 | 3 |
| 31 Mar 24 | 68 | 18 | 28 | 3 |
| 31 Dec 23 | 66 | 17 | 27 | 3 |
| 30 Sep 23 | 63 | 16 | 26 | 3 |
| 30 Jun 23 | 60 | 15 | 25 | 3 |
| 31 Mar 23 | 56 | 14 | 25 | 3 |
| 31 Dec 22 | 53 | 13 | 23 | 2 |
| 30 Sep 22 | 50 | 13 | 23 | 2 |
| 30 Jun 22 | 48 | 12 | 22 | 2 |
| 31 Mar 22 | 45 | 10 | 21 | 2 |
| 31 Dec 21 | 42 | 9 | 20 | 2 |
| 30 Sep 21 | 38 | 6 | 17 | 2 |
| 30 Jun 21 | 35 | 5 | 17 | 2 |
| 31 Mar 21 | 32 | 1 | 19 | 2 |
| 31 Dec 20 | 32 | 1 | 20 | 2 |
| 30 Sep 20 | 34 | 4 | 23 | 2 |
| 30 Jun 20 | 36 | 5 | 23 | 2 |
| 31 Mar 20 | 39 | 10 | 20 | 1 |
| 31 Dec 19 | 39 | 10 | 20 | 1 |
| 30 Sep 19 | 36 | 8 | 18 | 1 |
| 30 Jun 19 | 34 | 8 | 17 | 1 |
| 31 Mar 19 | 32 | 7 | 16 | 1 |
| 31 Dec 18 | 30 | 6 | 16 | 2 |
| 30 Sep 18 | 29 | 5 | 15 | 1 |
| 30 Jun 18 | 27 | 3 | 15 | 2 |
| 31 Mar 18 | 25 | 2 | 15 | 2 |
| 31 Dec 17 | 23 | 0 | 15 | 2 |
| 30 Sep 17 | 22 | 1 | 14 | 2 |
| 30 Jun 17 | 24 | 3 | 13 | 2 |
| 31 Mar 17 | 29 | 5 | 14 | 2 |
| 31 Dec 16 | 32 | 7 | 14 | 1 |
| 30 Sep 16 | 35 | 8 | 15 | 1 |
| 30 Jun 16 | 35 | 9 | 14 | 2 |
| 31 Mar 16 | 33 | 8 | 13 | 2 |
| 31 Dec 15 | 31 | 8 | 12 | 2 |
| 30 Sep 15 | 26 | 5 | 11 | 2 |
| 30 Jun 15 | 22 | 4 | 10 | 1 |
Kwaliteitswinsten: IRMD heeft hoge kwaliteitsinkomsten.
Groeiende winstmarge: De huidige netto winstmarges (27.4%) IRMD } zijn hoger dan vorig jaar (26.3%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: De winst van IRMD is de afgelopen 5 jaar aanzienlijk gegroeid met 25.4% per jaar.
Versnelling van de groei: De winstgroei van IRMD over het afgelopen jaar ( 19.3% ) ligt onder het 5-jarig gemiddelde ( 25.4% per jaar).
Winst versus industrie: De winstgroei IRMD over het afgelopen jaar ( 19.3% ) overtrof de Medical Equipment -sector 14.8%.
Rendement op eigen vermogen
Hoge ROE: Het Rendement op eigen vermogen ( 24% ) van IRMD wordt als hoog beschouwd.
Rendement op activa
Rendement op geïnvesteerd vermogen
Ontdek sterk presterende bedrijven uit het verleden
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/06/14 12:23 |
| Aandelenkoers aan het einde van de dag | 2026/06/12 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
IRADIMED CORPORATION wordt gevolgd door 4 analisten. 2 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Lawrence Solow | CJS Securities, Inc. |
| Ilya Zubkov | Freedom Broker |
| Frank Takkinen | Lake Street Capital Markets, LLC |